Document is current
Any future updates will be listed below
-
Authors
Raghunandan, Sharmila https://orcid.org/0000-0002-1149-8524
Gorfinkel, Lev
Bratrude, Brandi https://orcid.org/0000-0002-1498-1001
Suessmuth, Yvonne
Hebert, Kyle
Neuberg, Donna https://orcid.org/0000-0003-2566-3145
Williams, Kirsten M. https://orcid.org/0000-0001-9372-5286
Schoettler, Michelle L.
Langston, Amelia A. https://orcid.org/0000-0003-0649-1915
Kean, Leslie S.
Qayed, Muna
Horan, John
Watkins, Benjamin K. https://orcid.org/0000-0002-6675-8071
- License Information
-
More Information
Article History
Received: 2 June 2023
Revised: 15 June 2023
Accepted: 3 July 2023
First Online: 14 August 2023
Competing interests
: There is a relevant conflict of interest, described below. MLS reports Consultant/Honorarium at Omeros and Alexion. MQ reports Honoraria at Vertex and Novartis. LK reports the following—Novartis: Research Funding; Bluebird Bio: Research Funding; Vertex: Consultancy; EMD-Serono: Research Funding; Bristol Myers Squibb: Patents & Royalties: clinical trial, Research Funding; Magenta: Research Funding; Mammoth Biosciences: Current equity holder in private company, Current holder of stock options in a privately-held company; HiFiBio: Consultancy.
